Poop Transplants Could Be the Unexpected Fix for Doggy Dementia

Canine cognitive dysfunction (CCD), the dog equivalent of Alzheimer's disease, affects an estimated 14% to 35% of dogs older than eight years, and the condition only becomes more common as dogs age. Existing treatments offer modest benefit at best, leaving many pet owners watching helplessly as their dogs lose orientation, sleep through the day, and forget familiar faces. A small but intriguing pilot study published in the Journal of the American Veterinary Medical Association now offers a new lead: transplanting fecal material from healthy donors into the guts of cognitively impaired dogs may help slow or reverse that decline.

Fecal Microbiota Transplantation Improved Cognition in 4 of 6 Dogs

The study by Dewey, Rojas, Pomeroy, Gerardi, and Ganz, conducted between September 2024 and September 2025, enrolled 11 dogs with presumptive CCD. Each dog received oral fecal microbiota transplantation (FMT) capsules twice daily for 90 days. Owners rated their dogs using the DISHAA scale, a validated tool that scores seven behavioral domains: disorientation, impaired social interactions, sleep disturbance, house soiling, learning and memory loss, activity changes, and anxiety and fear. Scores above 4 indicate mild dysfunction; above 33 signals severe impairment.

Of the 6 dogs with complete 90-day data, 4 showed meaningful improvement, with a mean decrease of 8.25 DISHAA points. The other 2 dogs worsened, posting a mean increase of 7 points. That split is not reassuring in isolation, but the direction of the majority response, combined with microbiome shifts, is what gives researchers reason to push forward. Ten of the 11 enrolled dogs tolerated FMT without adverse events; one dog was withdrawn due to gastrointestinal signs.

Why Aging Dogs With CCD Represent an Urgent Clinical Need

35% is a striking prevalence figure for any condition, and current treatments for canine cognitive dysfunction have been rated by veterinarians as only slightly to moderately effective at best. Dogs most often receive their diagnosis between ages 13 and 15, by which point neurodegeneration is already well advanced. The situation mirrors what clinicians face in human Alzheimer's disease: a progressive condition with no disease-modifying therapy and a pipeline that keeps falling short.

CCD shares more than a behavioral resemblance with human Alzheimer's. The two conditions share neuropathological features including amyloid-beta protein deposition, neuroinflammation, and oxidative neuronal damage. That overlap is part of why researchers are watching FMT research in dogs closely: dogs may serve as a naturally occurring large-animal model for Alzheimer's interventions, making veterinary findings potentially relevant to human medicine as well.

How the Gut-Brain Axis Connects Microbiota to Memory

Dysbiosis, meaning an abnormal gut microbial population, has been linked to cognitive impairment in both rodent Alzheimer's models and human patients. The gut-brain axis, the two-way communication network linking gastrointestinal bacteria to brain function, operates through several routes: modulating short-chain fatty acid production, regulating systemic inflammation, and influencing tau protein phosphorylation and amyloid-beta accumulation in the brain.

FMT works by transferring fecal material from healthy donors into a recipient's gastrointestinal tract, aiming to restore a more normal microbial community. In this study, microbiome richness and diversity increased in 4 of the 6 dogs with complete data. Several dogs showed reductions in Streptococcus species and gains in potentially beneficial bacteria including Peptacetobacter hiranonis, Prevotella copri, and Bacteroides species. These shifts align with what rodent studies have found when dysbiosis is corrected: improved cognitive outcomes alongside favorable changes in gut flora.

Open Questions About Dosing, Duration, and Sample Size

This is early-stage, investigational research, and the limitations are significant. Eleven dogs is a tiny sample, and complete DISHAA data were available for only 6. The ideal FMT dose and treatment duration remain undefined. Owner-reported behavioral scores introduce subjectivity, and a 90-day window may not capture longer-term trajectories in either direction.

Safety also warrants continued attention. This study recorded just one withdrawal due to GI signs, but FMT adverse events in animals can include lethargy, vomiting, diarrhea, weight loss, and dehydration, as documented in a separate feline case series. A larger trial with placebo controls and longer follow-up will need to address both efficacy and safety more rigorously before FMT can be recommended as a standard-of-care adjunct.

What a Larger FMT Trial in Dogs Could Look Like

The authors conclude that a larger study with longer follow-up is warranted based on these preliminary results. Given the shared neuropathology between CCD and human Alzheimer's, a well-powered canine trial could serve double duty: validating FMT as a veterinary intervention while generating translational data relevant to human dementia research. The DISHAA tool provides a validated, scalable outcome measure that could accommodate a multicenter design.

For now, FMT should be considered only as an investigational adjunct therapy, not a replacement for existing CCD management strategies. Pet owners whose dogs show signs of cognitive decline, including nighttime restlessness, getting stuck in corners, or failing to recognize familiar people, should talk to their veterinarian about a formal CCD assessment and what clinical trials may be available. The gut-brain axis is a genuinely promising target; what this pilot study establishes is that the question is worth asking at larger scale.

Evidence rating

INVESTIGATIONAL — 75/100

Uncontrolled pilot study in 11 dogs (complete outcome data available for 6). Results are mixed and the absence of a control group means observed changes in cognitive scores cannot be attributed to FMT. Not yet replicated in any controlled trial.